Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Abramson Cancer Center at Penn Medicine

Reviewed by TrialFinderData Editorial Team · Updated

9 clinical trials · 9 recruiting · OTHER

Abramson Cancer Center at Penn Medicine has 9 clinical trials registered on ClinicalTrials.gov, with 9 actively recruiting participants. The trials listed below cover 12 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Abramson Cancer Center at Penn Medicine\'s Trial Portfolio

Abramson Cancer Center at Penn Medicine is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

9 of Abramson Cancer Center at Penn Medicine's 9 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Abramson Cancer Center at Penn Medicine's research footprint spans Breast Cancer (4 trials), Lung Cancer (1), and pulmonary-nodule-solitary (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Abramson Cancer Center at Penn Medicine's portfolio at 44% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Abramson Cancer Center at Penn Medicine

RECRUITINGPhase 2NCT04523857

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 441 location
Breast Cancer
RECRUITINGNCT02732171

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 6001 location
Breast Cancer
RECRUITINGNCT05968898

Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs)...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 3003 locations
Lung CancerPulmonary Nodule, Solitary
RECRUITINGNCT06610344

BHB & CAR-T for Lymphomas

The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 51 location
Large B-cell Lymphoma
RECRUITINGEarly Phase 1NCT05733715

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 301 location
Renal Cell Carcinoma
RECRUITINGNCT07048496

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 501 location
Bladder Cancer
RECRUITINGNCT05126290

CTNNA1 Familial Expansion Study

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 1001 location
Cancer Gene MutationGastric CancerBreast Cancer
RECRUITINGPhase 1NCT03760575

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 201 location
Mesotheliomas Pleural
RECRUITINGNCT06694181

Safe and Explainable AI

While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 3000001 location
Artifical InteligenceCardiologyBreast Cancer+1

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Abramson Cancer Center at Penn Medicine have on ClinicalTrials.gov?

Abramson Cancer Center at Penn Medicine has 9 clinical trials registered on the federal ClinicalTrials.gov registry, of which 9 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Abramson Cancer Center at Penn Medicine study?

Abramson Cancer Center at Penn Medicine's registered trials cover 12 conditions on ClinicalTrials.gov, led by Breast Cancer (4 trials), Lung Cancer (1 trial), pulmonary-nodule-solitary (1 trial), large-b-cell-lymphoma (1 trial), Renal Cell Carcinoma (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Abramson Cancer Center at Penn Medicine clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 9 trials tracked for Abramson Cancer Center at Penn Medicine.